Navigation Links
VBI, Mayo Clinic investigate link between fungal proteins, innate immunity and asthma
Date:2/27/2008

Blacksburg, Va. Researchers at Mayo Clinic and the Virginia Bioinformatics Institute (VBI) have received a second grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance understanding of the role of environmental fungi in chronic airway disorders. Recently NIAID awarded the researchers a further $1.8 million for these studies over a five-year period to investigate how the environmental fungus Alternaria triggers airway inflammation and bronchial asthma. Exposure to the fungus Alternaria has long been implicated in the development and exacerbation of asthma, especially life-threatening asthma, although little is known about the molecular events in the immune system that underlie the etiology and progress of this chronic disease. By understanding how the innate immune system responds to environmental stimuli and helps shape the adaptive immune system, scientists hope in the long term to develop more specific therapies as well as prevention strategies for bronchial diseases.

Principal Investigator Hirohito Kita, M.D., from Mayo Clinic, remarked: In this investigation, we will be looking closely at how fungal enzymes from Alternaria cause innate immune responses in a variety of cells and how they influence nave T cells in the immune system to differentiate into T helper 2 cells or Th2 cells, a process which takes place in partnership with antigen-presenting cells called dendritic cells. Th2 cells are part of the adaptive immune system and are linked to the events that lead to inflammation of the airway. He added: Th2 cells typically produce cytokine signaling molecules or interleukins and the production of these interleukins leads to the recruitment of a specific class of white blood cells (eosinophils) that usually destroy parasitic organisms larger than bacteria or viruses. Mounting evidence suggests that allergic airway disorders such as asthma and chronic sinusitis are actually the result of our bodies believing we a
'/>"/>

Contact: Barry Whyte
whyte@vbi.vt.edu
540-231-1767
Virginia Tech
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Does artificial intelligence help clinicians to recognize atrophic gastritis with thyroid disease?
2. HealthpointCapital, LLC Appoints Stephen H. Hochschuler, M.D. as Clinical Advisor
3. Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research
4. Pharsight to Present at eClinical Forum
5. PRA International to Open Expanded Clinical Pharmacology Center
6. Elsevier enhances clinical decision making with suite of Clinical Decision Support solutions
7. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy
8. Professional Products, Inc. Integrates Clinical Skills and Simulation Center at the Johns Hopkins Hospital
9. Algeta Receives IND Approval for Alpharadin(TM) to Commence Clinical Development in the USA
10. Cleveland Clinic Collaborates with Google
11. Derma Sciences Announces Several Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming APWCA Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...e University College of Medicine research team led...layer of regulation in the cell division cycle, wh...ay cancer begins. , Wang, an assistant professor..., said the findings will lead to an improved abili... of new drugs that kill cancer cells by inhibiting...
(Date:11/21/2008)...ewswire/ -- The Generic,Pharmaceutical Associatio...om,GPhA President and CEO Kathleen Jaeger regardi...on "Emerging Health Care Competition and Consumer ...onducting this roundtable demonstrates the,growin...ess to safe and,affordable biogenerics sooner rat...
(Date:11/21/2008)...USNewswire/ -- New research at West Virginia Univ... tobacco product aimed at young adults is catching...ds, Camel Snus - touted as a socially acceptable w...gh levels of nicotine. , , "Camel Snus cont..." said Bruce Adkins of the state Division of Tobac...
(Date:11/21/2008)...re-FirstCall/ -- Today, prescription drugs are the... 88 percent of patients suffering chronic conditio...onic condition account for 96 percent of all presc...l costs. A proprietary new pharmacy model develop.... (NYSE: MHS ) significantly reduces critical ga...
Breaking Medicine News(10 mins):Health News:GPhA Statement on FTC Roundtable on Biogenerics 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6
...h officials are all set to oil the wheels of retai...opose new regulations to allow for the operation o...lso encourage not-for-profit hospitals, community ... basic medical services. The proposed changes wer...
...ntified the first gene that is linked to Restless ...er that affects millions of people worldwide . RL...ering need to move the legs and is also a major ca...sleep disturbance. We now have concrete evidence t...
...from heart disease among younger Britons is slowin... research published ahead of print in the journal ...nary artery heart disease in England and Wales bet...gures.They used the data to calculate heart diseas...
...f more than a thousand prisoners has failed to sol...e and prisoner rehabilitation programmes, said th...niversary of the Ministry of Justices introduction...lleviate the overcrowding crisis in English and We...
Other Medicine News:Health News:Retail Health Clinics Start Shop 2Health News:Gene Linked With Restless Leg Syndrome Spotted Out 2Health News:Disquieting Slow Down in Heart Disease Deaths Among Under 55s 2Health News:Prison Healthcare Continues to Fail Despite Emergency Measures, Warns BMA 2
(Date:11/19/2008)...istical significance , , ISELIN, N.J., Nov.... (Nasdaq: PARS ) today announced results from it...ion (NE) drug delivery technology formulated with ...-center, randomized, double-blinded, placebo-contr...he Company,s 3% Diclofenac Diethanolamine NanoEmul...
(Date:11/18/2008)...all/ -- NeuroDiscovery Ltd (ASX:,NDL), a specialt...nt Company,and Sosei Group Corporation ("Sosei";...l biopharmaceutical company, today announce that N...linical efficacy data for NSL-043/SD118.,This inv...pathic pain and has,successfully completed Phase ...
(Date:11/18/2008)...gnosed, elderly AML patients , , PRINCETON,...cals today announced that the first patient has be...of CPX-351 (Cytarabine:Daunorubicin) Liposome Inje...id leukemia (AML). , , The first patient wa...al College of Cornell University and New York Pre...
(Date:11/12/2008)...Watson, Marilyn & James Simons and,Sherry Lansing ... 12 J. Craig Venter,Ph...Institute (JCVI), was,awarded the Double Helix Med...vember 6th at a gala event in New York City., Dr.... Dr. James D.,Watson for making each of their indi...
Breaking Medicine Technology:Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory 2ASTRO selects pediatric oncologist as 2008 honorary member 25838 1ASTRO selects pediatric oncologist as 2008 honorary member 25838 2Combination Therapy Helps to Combat Myeloma 25834 1Combination Therapy Helps to Combat Myeloma 25834 2Combination Therapy Helps to Combat Myeloma 25834 3Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York 7358 1Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York 7358 2Iowa State University researcher shows proteins have controlled motions 4624 1Iowa State University researcher shows proteins have controlled motions 4624 2
...patients treated with VELCADE, cyclophosphamide,a...ne 28, 2007 /PRNewswire-FirstCall/ -- Millennium,P...ation of results,from clinical trials of VELCADE b... / complete response(1) (CR) rates in previously,t...ngs were,presented at the prestigious 11th Interna...
...Synagis Decreases Incidence of Recurrent Wheeze by...Md., June 29, 2007,/PRNewswire-FirstCall/ -- Abbot...tudy, published in the July issue of Journal of,Pe...palivizumab),may reduce recurrent wheezing in prem...study showed that premature infants without,chroni...
Other Medicine Technology:Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 2Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 3Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 4Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 5Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 6New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 2New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 3New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 4New Study in Journal of Pediatrics Suggests Synagis (Palivizumab),May Reduce Subsequent Recurrent Wheezing in Preterm Infants 5
Healon vitreous aspirating cannula, 21 gauge.
Flexible silicone tip cannula allows atraumatic access through retinal tear or hole for aspiration of subretinal fluids. Silicone tube extends 6mm beyond end of cannula. Luer lock hub for easy, sec
Ultra thin wall .90 mm (20 g) cannula allows maximum flow rate, 6 mm in length. Cannula beveled for easy insertion through sclerotomy. 3201 has 16 cm (6 in) high pressure PVC tubing to allow injectio
...ective line of compact CO2 systems combines portab...ature an extremely accurate laser beam, as well as...cially advantageous for small operating theatres a.... Use of special contact tips and accessories allo...
Medicine Products: